Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, Fréchet-Jachym M, Robert J, Veziris N, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Schünemann HJ, Lienhardt C. Mbuagbaw L, et al. Among authors: hayrapetyan a. Emerg Infect Dis. 2019 May;25(5):936-943. doi: 10.3201/eid2505.181823. Emerg Infect Dis. 2019. PMID: 31002070 Free PMC article.
Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia.
Hewison C, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Kiria N, Yegiazaryan L, Chumburidze N, Kirakosyan O, Atshemyan H, Qayyum S, Lachenal N, Varaine F, Huerga H. Hewison C, et al. Among authors: hayrapetyan a. Int J Tuberc Lung Dis. 2018 Jul 1;22(7):766-772. doi: 10.5588/ijtld.17.0840. Int J Tuberc Lung Dis. 2018. PMID: 29914602
Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They?
Bastard M, Guglielmetti L, Huerga H, Hayrapetyan A, Khachatryan N, Yegiazaryan L, Faqirzai J, Hovhannisyan L, Varaine F, Hewison C. Bastard M, et al. Among authors: hayrapetyan a. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1228-1231. doi: 10.1164/rccm.201801-0019LE. Am J Respir Crit Care Med. 2018. PMID: 29969054 No abstract available.
Six-Month Response to Delamanid Treatment in MDR TB Patients.
Hewison C, Ferlazzo G, Avaliani Z, Hayrapetyan A, Jonckheere S, Khaidarkhanova Z, Mohr E, Sinha A, Skrahina A, Vambe D, Vasilyeva I, Lachenal N, Varaine F. Hewison C, et al. Among authors: hayrapetyan a. Emerg Infect Dis. 2017 Oct;23(10):1746-8. doi: 10.3201/eid2310.170468. Epub 2017 Oct 17. Emerg Infect Dis. 2017. PMID: 28767036 Free PMC article.
High prevalence of infection and low incidence of disease in child contacts of patients with drug-resistant tuberculosis: a prospective cohort study.
Huerga H, Sanchez-Padilla E, Melikyan N, Atshemyan H, Hayrapetyan A, Ulumyan A, Bastard M, Khachatryan N, Hewison C, Varaine F, Bonnet M. Huerga H, et al. Among authors: hayrapetyan a. Arch Dis Child. 2019 Jul;104(7):622-628. doi: 10.1136/archdischild-2018-315411. Epub 2018 Dec 6. Arch Dis Child. 2019. PMID: 30523172 Free PMC article.
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.
Tadolini M, Garcia-Prats AJ, D'Ambrosio L, Hewison C, Centis R, Schaaf HS, Marais BJ, Ferreira H, Caminero JA, Jonckheere S, Sinha A, Herboczek K, Khaidarkhanova Z, Hayrapetyan A, Khachatryan N, Urtkmelidze Ia, Loreti C, Esposito S, Matteelli A, Furin J, Varaine F, Migliori GB. Tadolini M, et al. Among authors: hayrapetyan a. Eur Respir J. 2016 Sep;48(3):938-43. doi: 10.1183/13993003.00705-2016. Epub 2016 Jun 23. Eur Respir J. 2016. PMID: 27338197 Free PMC article.
68 results